{
  "extraction_metadata": {
    "timestamp": "2025-10-01T15:19:10.316561",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 11,
    "temperature": 0.3
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "AT",
      "Outcomes": "diarrhoea, dilation, nausea, transaminase increase, creatinine increase, QTc time prolongation, response rate, progression-free survival",
      "ChunksUsed": 7,
      "ContextTokens": 1630
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "Outcomes": "overall survival, response rates, progression-free survival, adverse events, Karnofsky performance status, ECOG performance status",
      "ChunksUsed": 2,
      "ContextTokens": 346
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "Outcomes": "overall response rate, progression-free survival, overall survival, diarrhoea, ALT increase, AST increase, neutropenia, fatigue, febrile neutropenia",
      "ChunksUsed": 8,
      "ContextTokens": 1556
    },
    "EL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EL",
      "Outcomes": "progression-free survival, overall survival, safety data",
      "ChunksUsed": 1,
      "ContextTokens": 210
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "Outcomes": "overall survival, progression-free survival, objective response rate (RECIST 1.1), health-related quality of life, adverse effects, physical benefits, psychological benefits",
      "ChunksUsed": 20,
      "ContextTokens": 3853
    },
    "ES": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "ES",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 252
    },
    "EU": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EU",
      "Outcomes": "",
      "ChunksUsed": 1,
      "ContextTokens": 159
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "Outcomes": "serious side effects on the skin",
      "ChunksUsed": 7,
      "ContextTokens": 1391
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "Outcomes": "benefits of combination of locoregional treatment with systemic therapy, harms of combination of locoregional treatment with systemic therapy",
      "ChunksUsed": 1,
      "ContextTokens": 202
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "Outcomes": "overall survival, progression free survival, objective response rate, overall response rate, adverse events, quality of life",
      "ChunksUsed": 4,
      "ContextTokens": 708
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "Outcomes": "symptom control, preservation of quality of life, prolonged survival, pain, anxiety, ulceration",
      "ChunksUsed": 5,
      "ContextTokens": 970
    }
  }
}